Prasugrel Monotherapy After Percutaneous Coronary Intervention for Chronic Coronary Syndrome
Shinichiro Masuda, Kengo Tanabe, Patricia O Guimarães, Takashi Muramatsu, Yukio Ozaki, Fernando De Martino, Ken Kozuma, Scot Garg, Nozomi Kotoku, Kai Ninomiya, Shigetaka Kageyama, Pedro A Lemos, Yoshinobu Onuma, Patrick W Serruys · 2023
Read Prasugrel Monotherapy After Percutaneous Coronary Intervention for Chronic Coronary Syndrome by Shinichiro Masuda, Kengo Tanabe, Patricia O Guimarães, Takashi Muramatsu, Yukio Ozaki, Fernando De Martino, Ken Kozuma, Scot Garg, Nozomi Kotoku, Kai Ninomiya, Shigetaka Kageyama, Pedro A Lemos, Yoshinobu Onuma, Patrick W Serruys (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10920039.txt.
Description
Shinichiro Masuda and co-authors compared in 2023 two pilot studies of using a single anti-clotting drug after a heart stent procedure. Standard care pairs two such drugs, but dropping aspirin may cut bleeding risk. The pilots, run in Brazil and Japan, gave a drug called prasugrel alone right after stenting in patients with chronic heart disease.
Over three months of follow-up, the combined rate of death, heart attack, and stent clotting was very low, and no stent clots occurred. Serious bleeding was also rare. Doses differed between the two countries, and imaging use differed a lot too. The authors say the approach looks safe in low-risk patients, but a randomized trial is needed for proof.
Catalog record
| CREATOR | Shinichiro Masuda, Kengo Tanabe, Patricia O Guimarães, Takashi Muramatsu, Yukio Ozaki, Fernando De Martino, Ken Kozuma, Scot Garg, Nozomi Kotoku, Kai Ninomiya, Shigetaka Kageyama, Pedro A Lemos, Yoshinobu Onuma, Patrick W Serruys |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |